email article
In patients with inflammatory bowel disease (IBD), treatment with infliximab (Remicade) was associated with attenuated immunogenicity to a single dose of either the Pfizer or AstraZeneca COVID-19 vaccine, a large British cohort study found.
Concurrent use of an immunomodulator with infliximab, a tumor necrosis factor (TNF) inhibitor, further reduced immunogenicity to either vaccine, reported Tariq Ahmad, MD, of the Royal Devon and Exeter National Health Service (NHS) Foundation Trust in England, and colleagues. Delayed second dosing should be avoided in patients treated with infliximab, the researchers wrote in
.
Reassuringly, however, vaccination after SARS-CoV-2 infection or after a second dose of vaccine, led to seroconversion in most IBD patients.